These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21715709)

  • 1. Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.
    Devanand DP; Schupf N; Stern Y; Parsey R; Pelton GH; Mehta P; Mayeux R
    Neurology; 2011 Jul; 77(2):125-31. PubMed ID: 21715709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.
    Koivunen J; Pirttilä T; Kemppainen N; Aalto S; Herukka SK; Jauhianen AM; Hänninen T; Hallikainen M; Någren K; Rinne JO; Soininen H
    Dement Geriatr Cogn Disord; 2008; 26(4):378-83. PubMed ID: 18931497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.
    Ances BM; Benzinger TL; Christensen JJ; Thomas J; Venkat R; Teshome M; Aldea P; Fagan AM; Holtzman DM; Morris JC; Clifford DB
    Arch Neurol; 2012 Jan; 69(1):72-7. PubMed ID: 22232345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
    Weigand SD; Vemuri P; Wiste HJ; Senjem ML; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Jack CR;
    Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Aβ analysis using magnetically-labeled immunoassays and PET
    Wu KY; Hsiao IT; Chen CH; Liu CY; Hsu JL; Huang SY; Yen TC; Lin KJ
    Sci Rep; 2018 Feb; 8(1):2739. PubMed ID: 29426824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
    Tolboom N; van der Flier WM; Yaqub M; Koene T; Boellaard R; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    Neurology; 2009 Dec; 73(24):2079-85. PubMed ID: 20018636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study.
    Okello A; Edison P; Archer HA; Turkheimer FE; Kennedy J; Bullock R; Walker Z; Kennedy A; Fox N; Rossor M; Brooks DJ
    Neurology; 2009 Jan; 72(1):56-62. PubMed ID: 19122031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species.
    Oliveira F; Leuzy A; Castelhano J; Chiotis K; Hasselbalch SG; Rinne J; Mendonça A; Otto M; Lleó A; Santana I; Johansson J; Anderl-Straub S; Arnim C; Beer A; Blesa R; Fortea J; Sanna-Kaisa H; Portelius E; Pannee J; Zetterberg H; Blennow K; Moreira AP; Abrunhosa A; Nordberg A; Castelo-Branco M
    Neuroimage Clin; 2018; 20():603-610. PubMed ID: 30186764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
    Tolboom N; van der Flier WM; Yaqub M; Boellaard R; Verwey NA; Blankenstein MA; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    J Nucl Med; 2009 Sep; 50(9):1464-70. PubMed ID: 19690025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
    Cohen AD; Price JC; Weissfeld LA; James J; Rosario BL; Bi W; Nebes RD; Saxton JA; Snitz BE; Aizenstein HA; Wolk DA; Dekosky ST; Mathis CA; Klunk WE
    J Neurosci; 2009 Nov; 29(47):14770-8. PubMed ID: 19940172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.
    Svedberg MM; Hall H; Hellström-Lindahl E; Estrada S; Guan Z; Nordberg A; Långström B
    Neurochem Int; 2009; 54(5-6):347-57. PubMed ID: 19162107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.
    Perrotin A; Mormino EC; Madison CM; Hayenga AO; Jagust WJ
    Arch Neurol; 2012 Feb; 69(2):223-9. PubMed ID: 22332189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.